Boston Scientific Announces Schedule for Presentations at American College of Cardiology 2014
Includes Late Breaking Clinical Trial Assessing Use of the Boston Scientific CRT-D Therapyin Patients with Mild Heart Failure

NATICK, Mass., March 27, 2014 /PRNewswire/ -- At the 63rd Annual Scientific Session of the American College of Cardiology (ACC), March 29 – 31 in Washington, D.C., Boston Scientific Corporation (NYSE: BSX) will reinforce its commitment to research and development of innovative technologies to address global challenges in treating cardiovascular disease.

According to the World Health Organization, cardiovascular disease is the leading cause of death worldwide and is projected to remain so through at least 2030, emphasizing the critical need for new therapies.  The data being presented at this prestigious conference will provide new insight into the clinical and economic value of the Boston Scientific portfolio of technologies in cardiovascular disease.  Key presentations focus on areas of significant unmet needs, including coronary artery disease, aortic valve disease, heart failure and resistant hypertension.

"Boston Scientific is dedicated to bringing meaningful innovation and value-driven solutions to patients with cardiovascular disease around the world," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific.  "The data we are presenting at ACC 2014 confirm our commitment to advancing science and improving clinical outcomes."

Schedule of Key Data Presentations

All programs are Eastern Daylight Time, with events held at the Walter E. Washington Convention Center.

Saturday, March 29

  • PLATINUM Workhorse 4-year Outcomes
    • Dean Kereiakes will present four-year results from the PLATINUM Workhorse trial. This randomized, controlled trial enrolled 1,530 patients at 132 sites worldwide and compares the Boston Scientific Platinum Chromium Everolimus-Eluting Coronary Stent System to the Abbott Laboratories Cobalt Chromium Everolimus-Eluting Coronary Stent System. 
    • Oral presentation of data
    • 8:15 a.m. - 8:25 a.m. in Room 207A
  • Preclinical SYNERGY Stent System  
    • Michael Eppihimer will present preclinical data about the SYNERGYStent System that characterize the impact of polymer type and coating location on vascular inflammation and surface healing in a diseased swine model.
    • Data to be presented as a poster
    • 9:30 a.m.12:30 p.m. in Hall C
  • REPRISE II 3-month Outcomes
    • Ian Meredith will present results of the 120-patient REPRISE II study, evaluating transcatheter aortic valve replacement for severe symptomatic aortic stenosis using the repositionable Lotus Valve System.
    • Data to be presented as a poster
    • 10:00 a.m. - 10:45 a.m. in Hall C
  • Renal Denervation in Patients with Accessory Renal Arteries: Renal Mass Is Directly Proportional to Total Renal Artery Cross Sectional Area and Implications for Therapy
    • Robert S. Schwartz will present an evaluation of the renal mass and total arterial cross-sectional area in the kidneys of patients undergoing renal denervation using 3-D computed tomography.
    • Data to be presented as a poster
    • 3:45 p.m. - 4:30 Hall C
  • Bipolar Multi-electrode Balloon Catheter Radiofrequency Renal Denervation with the Vessix System: Preclinical Safety Evaluation
    • Gregory J. Wilson will present results from a preclinical safety study of a 7-French compatible renal denervation system.
    • Data to be presented as a poster
    • 3:45 p.m. - 4:30 p.m. in Hall C
  • Clinical and Cost Effectiveness of Renal Denervation with the Vessix System in Patients with Resistant Hypertension
    • Michael Weber will present data assessing the clinical and economic impact of renal denervation compared to best medical therapy in patients with resistant hypertension.
    • Data to be presented as a poster
    • 3:45 p.m. - 4:30 p.m. in Hall C
  • An Analysis of Patient Out-of-Pocket Spending for Stroke Prevention in Non-Valvular Atrial Fibrillation
    • Stacey L. Amorosi will present an economic analysis of Medicare patient out-of-pocket costs for three stroke prevention strategies in non-valvular atrial fibrillation.
    • Data to be presented as a poster
    • 3:45 p.m. - 4:30 Hall C
  • Cost Utility and Quality of Life Impact of Left Atrial Appendage Closure Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
    • Stacey L. Amorosi will present data about the cost effectiveness of left atrial appendage closure with the WATCHMAN Device relative to warfarin for stroke risk reduction in atrial fibrillation.
    • Data to be presented as a poster
    • 3:45 p.m. - 4:30 Hall C

Sunday, March 30

  • Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure
    • Ilan Goldenberg will present long-term follow-up results from MADIT-CRT, a prospective randomized trial comparing ICD to CRT-D therapy in patients with mild heart failure.  
    • Data to be presented in Late-Breaking Clinical Trials III presentation
    • 11:30 a.m. - 11:40 a.m. in Hall D

Monday, March 31

  • PERSEUS Final 5-year Outcomes
    • Dean Kereiakes will present an analysis of final, 5-year clinical outcomes in the PERSEUS Workhorse (ION vs. TAXUS™ Express) and PERSEUS Small Vessel (SV) (ION vs. bare metal Express) clinical studies.  
    • Data to be presented as a poster
    • 9:45 a.m. - 10:30 a.m. in Hall C

In addition to attending the data presentations, conference attendees are invited to visit the Boston Scientific booth (#1439) in the Exhibit Hall.

All clinical data results are embargoed until the time of each scientific presentation.

Caution:  In the U.S., the SYNERGY Stent System and the WATCHMAN Left Atrial Appendage (LAA) Closure Device are investigational devices, limited by federal (U.S.) law to investigational use only, and not available for sale.  In the U.S., the Lotus Valve System and the Vessix Renal Denervation System are under development and not available for use or sale.  All aforementioned devices are CE marked in the European Union.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding markets for our products, our business plans, presentations, clinical trials and impact of data, product performance and impact, and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

Media: Ryan Davenport
612-240-0492 (cell)
Global Media Relations
Boston Scientific Corporation 

Investors: Susie Lisa, CFA
508-652-5345 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation